Industrifonden invests in MinervaX as part of 57MUSD Series B

December 15, 2020

We are pleased to add MinervaX to the list of our portfolio companies.

Group B Streptococcus (GBS) is a leading cause of sepsis and meningitis in neonates and young infants, resulting in substantial mortality and morbidity. Maternal immunization against GBS would have significant benefits for the prevention of not only neonatal diseases but also GBS-associated stillbirth and preterm delivery. We are delighted to come together with such a strong syndicate to support MinervaX in making GBS diseases vaccine-preventable. We look forward to working with the MinervaX management team and our co-inventors to help accelerate the company’s development ambitiously.

Read more here:

By continuing on the site you accept our terms and conditions for cookies. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.